AI in Oncology Market to Reach US$ 22.85 Billion by 2033, Growing at 25.3% CAGR | North America Leads with 42% Share | Key Players: Tempus, Paige AI, ConcertAI, Azra AI

The AI in oncology market reached US$ 2.43 billion in 2024 and is expected to reach US$ 22.85 billion by 2033, growing at a CAGR of 25.3% during the forecast period 2025-2033. Market growth is driven by rapid advancements in artificial intelligence technologies, rising global cancer prevalence, and increasing focus on personalized and precision oncology. AI is being widely adopted across cancer imaging, early detection, treatment planning, clinical decision support, and drug discovery to improve outcomes and reduce diagnostic time.

Strong momentum is coming from heavy investments by pharmaceutical companies, healthcare providers, and technology firms in AI-powered diagnostic and therapeutic platforms. Regulatory support for AI-based cancer detection tools, along with growing collaboration between hospitals, research institutions, and AI developers, is accelerating clinical integration. Rising public awareness around early cancer screening and AI's ability to enhance diagnostic accuracy and speed are further strengthening market adoption, positioning AI as a transformative force in modern oncology care.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ai-in-oncology-market?sai-v

The AI in Oncology market refers to the sector of artificial intelligence solutions used to improve cancer diagnosis, treatment planning, drug discovery, and clinical decision-making.

Key Developments
✅ January 2026: In North America, adoption of AI in oncology expanded across major cancer centers and hospital networks, with AI-powered diagnostics, radiomics, and predictive analytics increasingly used to improve early detection, treatment planning, and clinical outcome forecasting.

✅ January 2026: In Europe, deployment of AI-enabled oncology imaging and clinical decision support systems increased as healthcare providers focused on standardizing diagnostics, reducing interpretation variability, and improving workflow efficiency across cancer care pathways.

✅ December 2025: In Asia-Pacific, integration of AI into oncology diagnostics and pathology workflows accelerated, supporting automated image analysis, personalized therapy recommendations, and improved access to cancer expertise through tele-oncology platforms.

✅ December 2025: Globally, integration of AI with multi-omics data (genomics, proteomics, and radiomics) advanced precision oncology, enabling improved biomarker discovery, therapy response prediction, and personalized treatment strategies.

✅ November 2025: In Latin America, increased adoption of AI-assisted oncology tools supported cancer screening, staging, and treatment monitoring, helping healthcare systems address workforce shortages and improve diagnostic accuracy.

✅ October 2025: Worldwide, AI-driven optimization of oncology clinical trials gained momentum, with machine learning models improving patient stratification, accelerating trial enrollment, and enhancing predictive assessment of treatment efficacy.

Mergers & Acquisitions
✅ January 2026: A global healthcare analytics provider acquired an AI-based oncology predictive modeling firm to strengthen clinical decision support capabilities and expand advanced cancer analytics solutions.

✅ December 2025: A precision medicine platform company acquired a genomic data interpretation and AI software developer to enhance multi-omics integration and personalized oncology treatment recommendations.

✅ November 2025: A medical imaging technology company acquired an oncology-focused AI imaging analytics developer to expand automated tumor detection, segmentation, and disease characterization capabilities across cancer types.

Key Players
Azra AI | CureMetrix, Inc. | ConcertAI | Immunai | MVision AI Inc. | Paige AI, Inc. | Mindpeak GmbH | Imagene AI Ltd. | Predictive Oncology | Tempus | Others

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ai-in-oncology-market?sai-v
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers
Increasing global cancer incidence and the rising need for early detection, accurate diagnosis, and personalized treatment strategies driving adoption of AI in oncology.

Growing volumes of complex clinical, imaging, genomic, and pathology data necessitating AI-enabled analytics for efficient interpretation and clinical decision support.

Advancements in machine learning, deep learning, and radiomics enhancing AI-based tools for tumor detection, segmentation, treatment planning, and outcome prediction.

Rising integration of AI in precision medicine initiatives enabling tailored therapy selection, risk stratification, and response monitoring in oncology care.

Expanding investments by healthcare providers, technology developers, and research institutions to implement AI solutions that improve oncology workflows and patient outcomes.

Industry Developments
Development and regulatory approval of AI-driven diagnostic platforms for automated interpretation of medical imaging (e.g., CT, MRI, PET) to aid early cancer detection.

Integration of AI in digital pathology, enabling automated analysis of histopathological slides, biomarker quantification, and prognostic modeling.

Emergence of AI-assisted clinical decision support systems (CDSS) combining patient data with evidence-based recommendations to guide treatment selection and therapy optimization.

Collaborative initiatives between AI technology firms, oncology centers, pharmaceutical companies, and academic institutions to co-develop validated oncology solutions.

Advancements in AI-enabled predictive models and virtual trials supporting drug discovery, clinical trial matching, and adaptive treatment strategies in cancer therapeutics.

Regional Insights
North America - 42% share: "Driven by strong digital health infrastructure, extensive clinical research ecosystems, early adoption of AI in healthcare, and investment in oncology innovation."

Europe - 27% share: "Supported by well-established cancer care systems, integrated healthcare data platforms, and collaborative AI oncology pilot programs."

Asia Pacific - 23% share: "Fueled by rising cancer burden, expanding healthcare digitization, increasing adoption of AI technologies, and government initiatives to improve oncology outcomes."

Latin America - 5% share: "Driven by growing awareness of advanced cancer care technologies, improving healthcare infrastructure, and gradual adoption of AI solutions in oncology."

Middle East & Africa - 3% share: "Supported by developing oncology services, investments in healthcare technology, and increasing focus on improving cancer diagnosis and management."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-oncology-market?sai-v


Key Segments
By Component Type
Software solutions dominate the market, driven by AI-powered platforms for imaging analysis, clinical decision support, workflow automation, and predictive analytics. Services are gaining traction as healthcare providers seek implementation support, data integration, model training, and ongoing maintenance. Hardware components, including high-performance computing systems and AI-enabled imaging devices, support data-intensive oncology applications and contribute to overall market growth.

By Cancer Type
Breast cancer represents a major segment due to high incidence rates and extensive use of AI in mammography, risk assessment, and treatment planning. Lung cancer is a key area for AI adoption, supported by the need for early detection and accurate imaging interpretation. Prostate cancer benefits from AI-driven pathology and radiology tools that improve diagnostic precision. Colorectal cancer is increasingly leveraging AI for screening and predictive analytics. Other cancer types include brain, skin, hematological, and gynecological cancers, where AI is expanding clinical and research applications.

By Application
Diagnostics account for the largest share, as AI enhances accuracy and speed in medical imaging, pathology, and screening programs. Treatment planning and therapy selection are growing segments, driven by personalized medicine and precision oncology approaches. Drug discovery and development benefit from AI-enabled target identification and clinical trial optimization. Other applications include patient monitoring, prognosis prediction, and clinical workflow management, supporting comprehensive oncology care.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.